A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, positive drug parallel controlled equivalence clinical
trial initiated at about 30 sites in China.
In the trial, it is planned to enroll 414 subjects, randomized to two treatment groups in a
ratio of 1:1 to receive the test drug and the positive control.